Publication|Videos|July 18, 2024
PurpleLab Accelerates Clinical Trial Lifecycle with Real-World-Data
Author(s)PurpleLab
Jason Gagner (Vice President of Product for Life Science, PurpleLab) talks about clinical trial variables and how PurpleLab is working to maintain patient retention and accelerate site feasibility.
Approximately 80% of clinical trials will face delays at some point in the trial process. Jason Gagner talked with ACT about how PurpleLab uses real-world data to better inform trials and improve their success rates.
Learn More About:
- Utilizing real-world data (RWD) to assist clinical trials achieve key milestones
- Employing a criteria specific geographic analysis of patient populations to expedite site feasibility assessments
- Understanding the impact of diversity, equity, and inclusion (DEI) in clinical trials on meeting trial objectives and timelines
- Integrating social determinants of health (SDOH) data to minimize patient dropout rates
Related Content
Trending on Applied Clinical Trials Online
1
Workflow in the Age of AI
2
The AI Churn Trap in Life Sciences and How to Break It
3
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
4
ACT Brief: Data Readiness Gap in Continuous Monitoring, Workflow-Centric AI Deployment, and First-in-Class ADHD Mechanism
5